文献速递主动脉疾病

使用INCRAFT支架系统进行腹主动脉瘤腔内修复:韩国多中心与单中心登记数据的联合分析

Endovascular Aneurysmal Repair With the INCRAFT Stent Graft System for Abdominal Aortic Aneurysms: A Combined Korean Multi-Center and Single-Center Registry Analysis.
PubMed 文献 · J Endovasc Ther · 2025-03-13

本研究联合韩国前瞻性多中心队列(n=85)和单中心回顾性队列(n=61)的腹主动脉瘤患者,评估INCRAFT支架系统腔内修复的疗效与安全性。技术成功率为82.9%,30天主要血管并发症率为0.7%,12个月主要不良事件率为6.2%(归因于非心血管死亡),无动脉瘤相关死亡或破裂。

要点

  • INCRAFT支架系统在韩国腹主动脉瘤患者中显示出良好的早期和12个月临床疗效与安全性。
  • 技术成功率为82.9%,主要因即刻血管造影下I型内漏发生率较高(17.1%)。
  • 30天主要血管并发症率为0.7%,12个月主要不良事件率为6.2%(非心血管死亡)。

核心结论

  • INCRAFT支架系统在治疗韩国腹主动脉瘤患者中表现出良好的早期和12个月临床疗效与安全性。

研究设计与样本

  • 研究人群包括前瞻性多中心队列(n=85)和单中心回顾性队列(n=61)的韩国腹主动脉瘤患者,均接受INCRAFT支架系统治疗。
  • 术后随访包括术后1个月和12个月的计算机断层扫描(CT)成像,以监测动脉瘤尺寸和检测内漏。

主要发现

  • 参与者平均年龄为72.0±7.1岁,男性占91.8%,平均最大主动脉囊直径为54.7±8.6 mm。
  • 技术成功率为82.9%,主要因即刻血管造影评估中I型内漏发生率较高(17.1%)。
  • 30天主要血管并发症率为0.7%;双侧股动脉入路止血中,57.5%仅需2个ProGlide。
  • 30天随访CT内漏发生率为30.4%,包括I型(1.4%)、II型(26.1%)和未明确型(2.8%)。
  • 12个月随访时主要不良事件率为6.2%(归因于非心血管死亡);动脉瘤相关事件包括3例(2.1%)再干预(移植物闭塞2例,II型内漏伴囊扩张1例);动脉瘤缩小和增大分别发生于37.8%和3.4%的患者;II型内漏最常见(22.7%),I型内漏和未明确型分别为0.8%和17.8%,无III型内漏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The INCRAFT™ Stent Graft System is a trimodular, bifurcated, ultra-low-profile endovascular device designed for endovascular aneurysm repair in patients with abdominal aortic aneurysm (AAA). MATERIALS AND METHODS: The study population comprised a prospective multi-center cohort (n = 85) and a single-center retrospective cohort (n = 61) of Korean AAA patients treated with INCRAFT. Postprocedural follow-up involved computed tomography (CT) imaging at 1 and 12 months post-procedure to monitor aneurysm dimensions and detect any endoleak. RESULTS: The mean age of participants was 72.0 ± 7.1 years, with the majority being male (91.8%). The average maximal aortic sac diameter was 54.7 ± 8.6 mm. Technical success was achieved in 82.9%, primarily due to the relatively high incidence of type I endoleak (17.1%) observed on immediate angiographical assessment. The rate of 30-day major vascular complication was 0.7%. For the hemostasis of bilateral femoral access arteries, 57.5% required only 2 ProGlides. At the 30-day follow-up CT, the prevalence of endoleaks was 30.4% including type I (1.4%), type II (26.1%), and undermined type (2.8%). At the 12-month follow-up, the major adverse event rate was 6.2% attributed to noncardiovascular mortality. Aneurysm-related events included 3 cases (2.1%) of re-interventions due to graft occlusion (n = 2) and type II endoleak with sac expansion (n = 1). Aneurysm shrinkage and enlargement occurred in 37.8% and 3.4% of patients, respectively. At the 12-month follow-up, type II endoleak was the most frequent type, with a prevalence of 22.7%. Type I endoleak and undetermined type were found in 0.8% and 17.8% of cases, respectively, with no instances of type III endoleak. CONCLUSION: INCRAFT demonstrated favorable early and 12-month clinical efficacy and safety profiles for treating Korean patients with AAA. TRIAL REGISTRATION: K-INCRAFT; www. CLINICALTRIALS: gov Identifier: NCT03952780Clinical ImpactEndovascular aneurysmal repair (EVAR) is effective treatment option for unruptured abdominal aortic aneurysm (AAA) in patients with high perioperative risk and suitable anatomy. The INCRAFT stent graft system is an ultra-low-profile endovascular graft designed for EVAR, and its efficacy and safety have been demonstrated in multi-center European and U.S. TRIALS: Our study found that the INCRAFT stent graft system has favorable early and 12-month clinical efficacy and safety profiles in treating AAAs within Korean population, with a 30-day major vascular complications rate of 0.7% and no cases of aneurysmal-related mortality or rupture.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Jin IT, Ko YG, Lee SJ, et al. Endovascular Aneurysmal Repair With the INCRAFT Stent Graft System for Abdominal Aortic Aneurysms: A Combined Korean Multi-Center and Single-Center Registry Analysis. J Endovasc Ther. 2025. PMID: 40079393. doi:10.1177/15266028251320510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。